31 May 2022
Oxford BioTherapeutics to present initial positive data from Phase I trial at ASCO 2022
• Initial data from Phase 1 dose escalation part of the trial, assessing OBT076 in adult patients with advanced solid tumors, indicated that OBT076 was generally well tolerated with no dose-limiting toxicities observed; optimal dose selected at 3.0 mg/kg. • OBT076 showed...
30 May 2022
NIHR backed AI care planning network goes live
English healthcare providers are now able to join a network that uses crowd sourced data to shape care plans. Healum, an artificial intelligence-based App, uses data that patients have chosen to share in order to personalise care recommendations and improve clinical decision...
26 May 2022
Oxford BioTherapeutics announces collaboration with Agenus
Oxford BioTherapeutics announces collaboration with Agenus to support the clinical development of OBT’s antibody drug conjugate OBT076 in combination with Agenus’ CPI Balstilimab … • New deal enables Oxford BioTherapeutics (OBT) to evaluate OBT076 with a checkpoint...
26 May 2022
CARB-X receives additional $370m from U.S. Government and Wellcome
Funding will enable continued investment in innovative projects to tackle the growing global threat posed by AMR … Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, welcomes the news that CARB-X (Combating Antibiotic...
25 May 2022
Blueberry Therapeutics provides regulatory update on Phase 2b trial
Alderley Park, 24 May 2022 – Blueberry Therapeutics has reported significant progress in its Phase 2b European trial of BB2603 in onychomycosis (BBTAF202). The COVID-19 pandemic led to operational challenges in all 3 participating countries (Germany, Poland and Czech...
17 May 2022
Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022 … Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, is pleased to announce it has received approval from the UK Medicines and Healthcare...
16 May 2022
Maxwellia appoints Ian Adamson as Strategic Advisor
Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a...
28 April 2022
Catapult Ventures records 3.3x return from exit of Panthera Biopartners
28 April 2022 - Manchester, UK. The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced a 3.3x cash return (115.6% IRR), from its exit of Panthera Biopartners Ltd. The exit comes as part of a £10m further funding package for Panthera from Business...
26 April 2022
Medicine switching expert Maxwellia continues to drive shift to self-care with two more pharmacy products in the launch pipeline
MANCHESTER, England, April 22, 2022 /PRNewswire/ -- Following the reclassification of the daily progestogen-only pill earlier this year, Maxwellia made history by launching Lovima® (desogestrel 75mcg) one of the first oral contraceptive brands to be available in pharmacy. It...
13 April 2022
Oxford BioTherapeutics grants third exclusive license to Boehringer Ingelheim
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target … OXFORD, England and SAN JOSE, Calif., April 13, 2022 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a clinical...